In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Clémenceau, Béatrice ^a,b   Valsesia Wittmann, Sandrine ^c   Jallas, Anne Catherine ^c   Vivien, Régine ^a   Rousseau, Raphaël ^d   Marabelle, Aurélien ^c   Caux, Christophe ^c   Vié, Henri ^a  

^a Team 12   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c CENTRE LÉON BÉRARD   (France)

^d Genenthec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CETUXIMAB; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; IMMUNOGLOBULIN G2; RITUXIMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; FCEPSILONRI GAMMA-CHAIN, HUMAN; FCGR3A PROTEIN, HUMAN; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PROTEIN INTERACTION; TARGET CELL; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; K562 CELL LINE; NONOBESE DIABETIC MOUSE; SCID MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS; CETUXIMAB; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; IMMUNOGLOBULIN G; K562 CELLS; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTOR, ERBB-2; RECEPTORS, IGE; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948783620     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/482089     Document Type: Article

References (26)

1. H. R. Koene, M. Kleijer, J. Algra, D. Roos, A. E. von dem Borne, and M. de Haas, "FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype," Blood, vol. 90, no. 3, pp. 1109-1114, 1997.
2. G. Cartron, L. Dacheux, G. Salles et al., "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene," Blood, vol. 99, no. 3, pp. 754-758, 2002.
3. B. Clémenceau, N. Congy-Jolivet, G. Gallot et al., "Antibodydependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes," Blood, vol. 107, no. 12, pp. 4669-4677, 2006.
4. B. Clémenceau, G. Gallot, R. Vivien, J. Gaschet, M. Campone, and H. Vié, "Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy," Journal of Immunotherapy, vol. 29, no. 1, pp. 53-60, 2006.
5. C.H. June, B.R. Blazar, and J. L. Riley, "Engineering lymphocyte subsets: tools, trials and tribulations," Nature Reviews Immunology, vol. 9, no. 10, pp. 704-716, 2009.
6. G. Gross, T. Waks, and Z. Eshhar, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 24, pp. 10024-10028, 1989.
7. Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 2, pp. 720-724, 1993.
8. Z. Eshhar, T. Waks, and G. Gross, "The emergence of Tbodies/CAR T cells," Cancer Journal, vol. 20, no. 2, pp. 123-126, 2014.
9. S. Gill and C. H. June, "Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies," Immunological Reviews, vol. 263, no. 1, pp. 68-89, 2015.
10. R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C.M. Laurencot, and S. A. Rosenberg, "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2," Molecular Therapy, vol. 18, no. 4, pp. 843-851, 2010.
11. L. Boissel, M. Betancur, W. Lu et al., "Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity," Onco Immunology, vol. 2, no. 10, Article IDe26527, 2014.
12. D.V. Tassev, M. Cheng, and N.-K. Cheung, "Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor," Cancer Gene Therapy, vol. 19, no. 2, pp. 84-100, 2012.
13. S. Uchiyama, Y. Suzuki, K. Otake et al., "Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope," Cancer Science, vol. 101, no. 1, pp. 201-209, 2010.
14. K. Schönfeld, C. Sahm, C. Zhang et al., "Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor," Molecular Therapy, vol. 23, no. 2, pp. 330-338, 2015.
15. O. H. Brekke, T. E. Michaelsen, and I. Sandlie, "The structural requirements for complement activation by IgG: does it hinge on the hinge?" Immunology Today, vol. 16, no. 2, pp. 85-90, 1995.
16. S. Wilkie, G. Picco, J. Foster et al., "Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor," Journal of Immunology, vol. 180, no. 7, pp. 4901-4909, 2008.
17. R. D. Guest, R. E. Hawkins, N. Kirillova et al., "The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens," Journal of Immunotherapy, vol. 28, no. 3, pp. 203-211, 2005.
18. B. Savoldo, C. A. Ramos, E. Liu et al., "CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients," The Journal of Clinical Investigation, vol. 121, no. 5, pp. 1822-1826, 2011.
19. A. Hombach, A. A. Hombach, and H. Abken, "Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response," Gene Therapy, vol. 17, no. 10, pp. 1206-1213, 2010.
20. B. G. Till, M. C. Jensen, J. Wang et al., "CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results," Blood, vol. 119, no. 17, pp. 3940-3950, 2012.
21. M. Casucci, B. N. di Robilant, L. Falcone et al., "CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma," Blood, vol. 122, no. 20, pp. 3461-3472, 2013.
22. M. Hudecek, D. Sommermeyer, P. L. Kosasih et al., "The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity," Cancer Immunology Research, vol. 3, no. 2, pp. 125-135, 2015.
23. P. Bruhns, B. Iannascoli, P. England et al., "Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses," Blood, vol. 113, no. 16, pp. 3716-3725, 2009.
24. P. Bruhns, "Properties of mouse and human IgG receptors and their contribution to disease models," Blood, vol. 119, no. 24, pp. 5640-5649, 2012.
25. M. B. Overdijk, S. Verploegen, A. Ortiz Buijsse et al., "Crosstalk between human IgG isotypes andmurine effector cells," Journal of Immunology, vol. 189, no. 7, pp. 3430-3438, 2012.
26. S. Swift, J. Lorens, P. Achacoso, and G. P. Nolan, "UNIT 10.17C Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems," in Current Protocols in Immunology, J. E. Coligan, B. Bierer, D.H. Margulies et al., Eds., chapter 10, John Wiley & Sons, 2001.